The treatment could relieve haemophilia B patients from factor IX replacement drugs UniQure has enrolled the first patient in its registration trial of haemophilia B gene therapy candidate AMT-061 as it tries to keep ahead of a rival project from Spark Therapeutics/Pfizer. The subject is the first out of around 50 subjects that will be recruited into the open-label HOPE-B trial of AMT-061, an a...